Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Mesoblast ( (MESO) ) is now available.
On March 20, 2026, Mesoblast filed a series of disclosures with the Australian Securities Exchange detailing changes in directors’ interests, primarily through the issuance of new options approved by shareholders at the company’s 2025 annual general meeting. The updates, later furnished to the U.S. Securities and Exchange Commission on March 23 via a Form 6-K, confirm additional option grants to chief executive Silviu Itescu, director Eric Rose and director Gregory George, reinforcing equity-based incentives while leaving their underlying ordinary share and ADS holdings largely unchanged, and signaling continued reliance on option awards as a key component of the company’s executive and board remuneration structure.
These option issuances, which carry no cash consideration to the directors, modestly increase potential future equity dilution but are intended to better align board and management incentives with long-term shareholder value creation. For investors, the filings provide transparency on governance and capital structure developments, indicating that Mesoblast is using its employee and director share option plans to retain and motivate key leadership as it pursues its strategic and clinical objectives in a competitive biotech landscape.
The most recent analyst rating on (MESO) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Mesoblast stock, see the MESO Stock Forecast page.
Spark’s Take on MESO Stock
According to Spark, TipRanks’ AI Analyst, MESO is a Neutral.
The score is held back primarily by weak financial performance (ongoing losses and cash outflows) and soft technical momentum. These are partially offset by a positive earnings-call outlook, including raised commercial evidence for Ryoncil (strong H1 revenue contribution, 93% gross margin) and clear revenue guidance, while valuation signals are limited due to an unusable P/E and no dividend.
To see Spark’s full report on MESO stock, click here.
More about Mesoblast
Mesoblast Limited is an Australia-incorporated biotechnology company focused on developing and commercializing cell-based and regenerative medicine therapies. The company is listed on the Australian Securities Exchange and has American Depositary Shares trading in the U.S., giving it a dual-market investor base spanning Australian and international shareholders.
Average Trading Volume: 233,165
Technical Sentiment Signal: Hold
Current Market Cap: $1.86B
Find detailed analytics on MESO stock on TipRanks’ Stock Analysis page.